Embed Size (px)
Citation preview
Il Polo senese ed il Distretto regionale scienze della vita nella prospettiva
europea
Dr. Francesco Maria Senatore
Business Development
Toscana Life Sciences Foundation
TLS 2013
Argomenti
• Polo Senese: TLS• Distretto: Cluster Regionale• Il mercato della Salute in Europa• Le necessità delle imprese• Evoluzione del Cluster
TLS 2013
TLS 2013
www.toscanalifesciences.org
TLS 2013
TLS Mission
Public Institutions
MPS
University
Applied Research Results
Industrial Development
Territory
Siena - The Science Park Monothematic : Life Sciences (Red Biotech)
drugs diagnostics medical devices biomedical technologies
Laboratories, offices, equipment and utilities
Consulting services and support
Access to public and private financing tools
JCVI April 2012
Total surface area: 83.000 sq. mt.
Total buildings surface: 38.400 sq. mt.
Labs (research/devel./Q.A.): 8.200 sq. mt.
Production plants: 6.800 sq. mt.
Warehouses: 2.800 sq. mt.
Offices: 8.400 sq. mt.
Services: 4.700 sq. mt.
TLS bio-incubator
Industrial and academic research activities
Center of excellence for Novartis Vaccines
More than 470 researchers
Common facilities, services and utilities
Science Park Location: Siena - Novartis site
JCVI April 2012
TLS Bio-incubator 10 laboratory modules (ranging from 60 to 140 m2) fully
equipped according to company’s needs
GMP facility for medicinal products derived from human blood
or plasma (160 m2)
Analytical labs and common services (135 m2)
BSL 3 lab
Animal care facility
Offices, meeting rooms (600 m2)
JCVI April 2012
TLS - Main Incubation ServicesIntellectual property protection consultancy
Technology Transfer/Start-up Creation
Business development coaching
Grants search and application support
Scouting of industrial and financial partners
Bio-partnering support Infrastructure Services (Front office, meeting room, etc.) Dedicated scientific equipment up to € 200k Common high-tech equipment and facilities
JCVI April 2012
Incubation Deal-Flow: the ”Picking the Winner Approach”
International Call for Application
Business Plan submission
Project selection
TLS Executive Board approval
Incubation
Find Start up financing
JCVI April 2012
JCVI April 2012
TLS Evaluation Committee
Dr. Bertil Samuelsson, Stockholm (SE)Dr. Eva Pisa, Stockholm (SE)
Dr. Andy Richards, Cambridge (UK)
Prof. Stephen Hanessian, Montréal (CA)
Dr. Elkan Gamzu, Boston (USA)
Torre Fiorentina Campus – September 2005
JCVI April 2012
TLS 2013
Companies and Research Groups 2013
TLS Performance Indicators
TLS 2013
2007 2010 2011 2012
Employees 10 70 93 112
Scientific Publications - 15 48 63
Patent Applications 8 25 22 24
Granted Patents 5 24 25 27
Collab./Agreem./Licensing 8 34 48 66
Diagnostics Prototypes - 6 8 23
Compounds in Clinical Phases - 1 1 2
Products on the Market - - - 22
Investments Attraction 12M 25M 32.7 M 44.0 M
Companies Revenue - - 1.5 M 3.1 M
TLS Incubated Companies & Research Groups: Total Financial Resources
Companies and Research Groups Financial Resources (2011)
Companies % Companies & Research Group %Stakeholders Investment 17.879.159 47,7 18.689.159 42,5Local Seed Funds 6.280.000 16,7 6.280.000 14,3Regional Seed Funds 2.350.000 6,3 2.350.000 5,3Other Funds 2.350.000 6,3 2.350.000 5,3Grants 8.609.809 23 14.354.409 32,6TOTAL 37.468.967 100 44.023.567 100
JCVI April 2012
TLS 2013
Universities and Research Centers
JCVI April 2012
Tuscany -Health Care System Quality
“33,9% of total clinical trials carried out in Italy are performed in Tuscany”
JCVI April 2012
TLS 2013
Head office : FlorenceEmployees : 3.000 in Tuscany, over 13.000
worldwideTurnover: € 3.004 Mil.
Head office: Siena Employees: 2.400
Turnover: € 652 Mil.
Head office : LuccaEmployees: 1.240
Turnover: € 240 Mil.
Head office : Sesto Fiorentino (FI)
Employees : 961Turnover: € 628 Mil.
Head office : FlorenceEmployees : 719
Turnover: € 214 Mil.
Head office : Calenzano (FI)Employees: 1.139
Turnover: € 211 Mil.
Some Big Players
TLS 2013
Tuscany is a strategic region in the Life Science
Companies Italy Tuscany % Tuscany
Biotech 221 30 14
Pharma 198 20 10
Medical Devices 2.735 156 6
Turnover ( € Mil .) Italy Tuscany % Tuscany
Biotech 7.157 1.630 23
Pharma 25.000 3.300 13
Medical devices 16.800 811 5
10.940 645 6Pharma Services
TLS 2013
Affiliated Companies 104 Employees 10.646 R&D Employees 1.376 Turnover in € Mil. 5.233 Labs square meters 31.203 Patents 775
TLS 2013
Member Representatives
Committee
Steering Committee
Public Institutions
Entrepreneurial System
National &
international clusters
Services Needs
Tuscany Life Sciences Cluster
The Tuscany Life Science Cluster
EU Healthcare Market
TLS 2013
Organisation for Economic Co-operation and Development (
OECD)
www.oecd.org/
TLS 2013
TLS 2013
• Growth in health spending per capita slowed or fell in real terms in 2010 in almost all European countries, reversing a trend of steady increases.
• Spending had already started to fall in 2009 in countries hardest hit by the economic crisis but this was followed by deeper cuts in 2010 in response to growing budgetary pressures and rising debt-to-GDP ratios.
• On average across the EU, health spending per capita increased by 4.6% per year in real terms between 2000 and 2009, followed by a fall of 0.6% in 2010.
TLS 2013
TLS 2013
• Reductions in public spending on health were achieved through a range of measures, including reductions in wages and/or employment levels, increasing direct payments by households for certain services and pharmaceuticals, and imposing severe budget constraints on hospitals.
• Gains in efficiency have also been pursued through mergers of hospitals or accelerating the move from inpatient care to outpatient care and day surgery.
TLS 2013
• The public sector is the main source of health care financing in all European countries.
• In 2010, nearly three-quarter (73%) of all health spending was publicly financed on average in EU member states.
• Public financing accounted for over 80% in the Netherlands, the Nordic countries (except Finland), Luxembourg, the
Service support to Life Science SME
TLS 2013
TLS 2013
Internazionalization is a challenge for SMEs
TLS 2013
• Align your product portfolio to the markets with high growth potential (market Analysis)
• Develop market-entry and market-expansion strategies by identifying the regions and market segments poised for strong growth (Strategic Positioning)
• Create a more tailored country strategy through the understanding of market outlook and major trends (local link)
• Develop key strategic initiatives by understanding the key focus areas and top-selling products of leading companies (match making events)
SME’s support need for foreign markets
Internationalization support
Deep insight intocompanies’ needs
Network of selected andqualified partners
Framework agreementswith institutional partners
Networking Europe’s Biocommunities
TLS 2013
ALISEI, Cluster nazionale Scienze della Vita
“Advanced LIfe SciEnces in Italy”
National Technology Cluster Call• The MIUR (Ministry of Education, Universities and Research) published a call
for the creation of 9 National Technological Clusters corresponding to different high tech sectors, one of them is Life Science
• For each sector only a single cluster has been created • Each Cluster presents 4 R&D projects
a) Total costs in between 10 and 12 millions of euro
b) A maximum of 8 proponents
c) Industrial partners covering at least the 50% of costs, with SME’s covering at least the 15%
d) Public partners covering at least the 35% of costs
• The MIUR supports the call with 368 millions of euro, 63 millions as a contribution to the costs and 305 as subsidized credit. Moreover the MIUR allocates additional 40 millions of euro of contribution for projects involving Puglia, Calabria, Sicilia and Campania regions.
Perchè un Cluster• Nuove dinamiche di sviluppo verso le economie basate sulla conoscenza e
l’innovazione. Tra i fattori in grado di sostenere e promuovere la transizione vi sono le “reti di conoscenza”.
• In linea con iniziative a livello europeo, come la Strategia di Lisbona e la “Europe 2020 Growth Strategy”, nella logica di un recupero di competitività grazie allo sviluppo di un’economia basata sulla conoscenza e sull’innovazione.
• Una delle criticità che si intende superare con il Cluster è rappresentata dalla frammentazione delle iniziative nell’ambito Scienze della Vita: senza adeguata massa critica mancano effettive ricadute per l’intero sistema Paese.
• L’ambizione è quella di favorire l’aggregazione di risorse non solo a livello regionale, ma anche tra i poli di riferimento nazionali e di entrare nelle grandi reti di aggregazione europee, partecipando ai “mega cluster” transnazionali che connettono i nodi specializzati esistenti in ciascun Paese (“Biotechnology strategy and action plan” della Commissione Europea )
ALISEI - gli attori• ALISEI raccoglie strutture
produttive e di ricerca, individuali e aggregate, appartenenti a 12 Regioni
• In ALISEI sono rappresentate le Associazioni di categoria: Assobiomedica, Assobiotec, Farmindustria e vi partecipa il sistema pubblico della ricerca: CNR, ENEA, ICE, IIT
• La governance di ALISEI è aperta, per accogliere ulteriori componenti scientifiche, industriali e istituzionali coerenti con la sua missione
ALISEI: Cluster Strategic positioning• Vision: To be a driving force in the economic growth of Italian regions in the
field of human health
• Mission: To establish a national network of skills and capacities of research, innovation and industrial development in the Life Science sector with the aim of answering the social and economic challenges in the field of human health
• Timeline: At least 5 years
• Macrotrends:
a) Personalized approach and integration between therapy and diagnosis
b) Ageing and chronic diseases
c) Convergent technologies
TLS 2013
2011
2016
2018
2020
Geo
gra
ph
ical
Are
a
Virtual cluster integration
Relevance of geographical proximity
Fonte: TLS elaboration from Sternberg (2003)
[-]
[++]
[++]
[-]
Local level
Regional level
National level
European Level
International Level
Science Park
Cluster
Super Cluster
Mega Cluster
The future
Thank youFrancesco Maria Senatore
Business Development
Communication & Projects
Tuscany Life Science Cluster & Foundation
Via Fiorentina, 1
53100 Siena ITALY
Tel.: +39 0577 231207
Mobile:+39 340 0917237
Fax: +39 0577 43444
www.toscanalifesciences.org
TLS 2013
TLS 2013
• International visibility is key for R&D intensive and start-up companies
• International presence is key for mature/expansion companies
• Both types of SME can’t approach the market alone
• Science Parks and Cluster organizations play a very important role in building up a real international network is key and should go beyond the EU
Conclusions
41
National Cluster ranking
41
TLS 2013
Post-Incubation Building
TLS 2013
International Benchmarking
TLS 2013
FM Senatore Bio-Europe
Cluster CompaniesBay Area - San Francisco (California) 715
Maryland 350
San Diego (California) 240
Boston (Massachusetts) 220
Philadelphia (Pennsylvania) 135
From V. Chiesa – Bioforum, Milano 2007
Biotech clusters in US
FM Senatore Bio-Europe
46
Cluster CompaniesCambridge (UK) 422
Biovalley (France – Germany – Switzerland) 320
Munich (Germany) 150
Heidelberg (Germany) 121
Berlin – Brandeburg (Germany) 115
Medicon Valley (Sweden – Denmark) 110
Edinburgh Dundee Glasgow (UK) 75
Oxford (UK) 85
Evry – Ile de France (France) 54
From V. Chiesa – Bioforum, Milano 2007
Biotech clusters in EU
